Variability of effluent cancer antigen 125 and interleukin-6 determination in peritoneal dialysis patients

Nephrology Dialysis Transplantation

Volumn 26, Issue 11, 2011, Pages 3739-3744

  Lopes Barreto, Deirisa ^a   Coester, Annemieke M ^a   Noordzij, Marlies ^a   Smit, Watske ^a,b   Struijk, Dirk G ^a,b   Rogers, Susan ^b   De Waart, Dirk R ^a   Krediet, Raymond T ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Dianet Foundation Amsterdam Utrecht   (Netherlands)

Author keywords

biomarkers; cancer antigen 125; interleukin 6; mesothelial cells; peritoneal dialysis

Indexed keywords

CA 125 ANTIGEN; INTERLEUKIN 6;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL PRACTICE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; ENZYME IMMUNOASSAY; FEMALE; GENETIC VARIABILITY; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PERITONEAL DIALYSIS; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN FUNCTION;

BIOLOGICAL MARKERS; CA-125 ANTIGEN; DIALYSIS SOLUTIONS; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 80155171898     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr170     Document Type: Article

References (21)

1. Visser CE, Brouwer-Steenbergen JJE, Betjes MGH et al. Cancer antigen 125: A bulk marker for the mesothelial mass in stable peritoneal dialysis patients. Nephrol Dial Transplant 1995; 10: 64-69
2. Koomen GC, Betjes MG, Zemel D et al. Dialysate cancer antigen (CA) 125 is a reflection of peritoneal cell mass in CAPD patients. Perit Dial Int 1994; 14: 132-136
3. Krediet RT. Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis. Perit Dial Int 2001; 21: 560-567
4. Ho-dac-Pannekeet MM, Hiralall JK, Struijk DG et al. Markers of peritoneal mesothelial cells during treatment with peritoneal dialysis. Adv Perit Dial 1997; 13: 17-22
5. Dobbie JW. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int 1992; 12: 14-27
6. Ho-dac-Pannekeet MM, Hiralall JK, Struijk DG et al. Longitudinal follow-up of CA125 in peritoneal effluent. Kidney Int 1997; 51: 888-893
7. Di Paolo N, Sacchi G. Atlas of peritoneal histology. Perit Dial Int 2000; 20 (Suppl 3): S5-S96
8. van Snick J. Interleukin-6: An overview. Annu Rev Immunol 1990; 8: 253-278
9. Aarden LA, de Groot ER, Schaap OL et al. Production of hybridoma growth factor by human monocytes. Eur J Immunol 1987; 17: 1411-1416
10. Topley N, Jorres A, Luttmann W et al. Human peritoneal mesothelial cells synthesize interleukin-6: Induction by IL-1 beta and TNF alpha. Kidney Int 1993; 43: 226-233
11. Zemel D, Betjes MG, Dinkla C et al. Analysis of inflammatory mediators and peritoneal permeability to macromolecules shortly before the onset of overt peritonitis in patients treated with CAPD. Perit Dial Int 1995; 15: 134-141
12. Zemel D, Koomen GC, Hart AA et al. Relationship of TNF-alpha, interleukin-6, and prostaglandins to peritoneal permeability for macromolecules during longitudinal follow-up of peritonitis in continuous ambulatory peritoneal dialysis. J Lab Clin Med 1993; 122: 686-696
13. Sampimon DE, Korte MR, Lopes Barreto D et al. Early Diagnostic Markers for encapsulating peritoneal sclerosis: A case - control study. Perit Dial Int 2010; 30: 163-169
14. Smit W, Schouten N, van den Berg N et al. Analysis of the prevalence and causes of ultrafiltration failure during long-term peritoneal dialysis: A cross-sectional study. Perit Dial Int 2004; 24: 562-570
15. Rodrigues AS, Martins M, Korevaar JC et al. Evaluation of peritoneal transport and membrane status in peritoneal dialysis: Focus on incident fast transporters. Am J Nephrol 2007; 27: 84-91
16. Imholz AL, Koomen GC, Voorn WJ et al. Day-to-day variability of fluid and solute transport in upright and recumbent positions during CAPD. Nephrol Dial Transplant 1998; 13: 146-153
17. Parikova A, Smit W, Struijk DG et al. The contribution of free water transport and small pore transport to the total fluid removal in peritoneal dialysis. Kidney Int 2005; 68: 1849-1856
18. van Esch S, Zweers MM, Jansen MA et al. Determinants of peritoneal solute transport rates in newly started nondiabetic peritoneal dialysis patients. Perit Dial Int 2004; 24: 554-561
19. Pecoits-Filho R, Araujo MR, Lindholm B et al. Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate. Nephrol Dial Transplant 2002; 17: 1480-1486
20. Pecoits-Filho R, Carvalho MJ, Stenvinkel P et al. Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis. Perit Dial Int 2006; 26: 53-63
21. Akman S, van Westrhenen R, de Waart DR et al. The effect of dwell time on dialysate cancer antigen 125 appearance rates in patients on continuous ambulatory peritoneal dialysis. Adv Perit Dial 2003; 19: 24-27